Chronic kidney disease (CKD) is defined as abnormalities in kidney structure or function that are present for more than 3 months and have health implications. The disease is classified on the basis of cause and category of glomerular filtration rate (GFR) (G1 to G5) and albuminuria (A1 to A3) (Appendix Figure, available at Annals.org). As kidney function decreases, marked changes in bone mineral metabolism occur, resulting in increased risk for fractures, cardiovascular disease, and overall mortality. In 2009, Kidney Disease: Improving Global Outcomes (KDIGO) published the Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD–MBD) (1). Based on evidence from new clinical trials, an updated clinical practice guideline was published in 2017 (2).

The 2017 update (available at www.kdigo.org) provides recommendations for diagnosis of bone abnormalities in CKD–MBD, treatment of CKD–MBD by decreasing serum phosphate levels and maintaining serum calcium levels, treatment of parathyroid hormone (PTH) abnormalities in CKD–MBD, treatment of bone abnormalities using antiresorptive agents and other osteoporosis therapies, and evaluation and treatment of kidney transplant bone disease (2). This synopsis focuses on diagnosis of CKD–MBD and management of serum phosphate, calcium, and PTH levels in adults—areas in which controversy and knowledge gaps exist. Recommendations for children and kidney transplant recipients are not addressed in this synopsis, but interested readers can refer to the guideline update for details (2).

A consolidated listing of CKD–MBD guideline statements relevant to adults with CKD stage G3a to G5 and those receiving dialysis, including the revised recommendations in the 2017 guideline update, is provided in the Table. The target audience for the guideline includes nephrologists, primary care physicians, and other health professionals caring for adults with CKD or those receiving dialysis.

GUIDELINE DEVELOPMENT PROCESS, EVIDENCE GRADING, AND STAKEHOLDER AND PUBLIC CONSULTATION

The KDIGO Controversies Conference, held in October 2013, determined that there was sufficient new evidence to support updating some of the CKD–MBD recommendations (3). The guideline update process began with the formation of an international Work Group and an independent evidence review team through February 2017. Final modification of the guidelines was informed by a public review process involving numerous stakeholders, including patients, subject matter experts, and industry and national organizations.

Recommendations: The update process resulted in the revision of 15 recommendations. This synopsis focuses primarily on recommendations for diagnosis of and testing for CKD–MBD and treatment of CKD–MBD that emphasizes decreasing phosphate levels, maintaining calcium levels, and addressing elevated parathyroid hormone levels in adults with CKD stage G3a to G5 and those receiving dialysis. Key elements include basing treatment on trends in laboratory values rather than a single abnormal result and being cautious to avoid hypercalcemia when treating secondary hyperparathyroidism.
Table: Consolidated KDIGO Guideline Recommendations for Adults With CKD Stage G3a to G5D and CKD-MBD*

Chapter 3.1: Diagnosis of CKD-MBD: Biochemical Abnormalities
3.1.1: We recommend monitoring serum levels of calcium, phosphate, PTH, and alkaline phosphatase activity beginning in CKD G3a. (Grade 1C recommendation)
3.1.2: In patients with CKD G3a to G5D, it is reasonable to base the frequency of monitoring serum calcium, phosphate, and PTH on the presence and magnitude of abnormalities, and the rate of progression of CKD. (Not graded)
Reasonable monitoring intervals would be:
• In CKD G3a to G3b: for serum calcium and phosphate, every 6–12 months; and for PTH, based on baseline level and CKD progression
• In CKD G4: for serum calcium and phosphate, every 3–6 months; and for PTH, every 6–12 months
• In CKD G5, including GSD: for serum calcium and phosphate, every 1–3 months; and for PTH, every 3–6 months
• In CKD G4 to G5D: for alkaline phosphatase activity, every 12 months, or more frequently in the presence of elevated PTH (see Chapter 3.2)
In CKD patients receiving treatments for CKD-MBD, or in whom biochemical abnormalities are identified, it is reasonable to increase the frequency of measurements to monitor for trends and treatment efficacy and side effects. (Not graded)
3.1.3: In patients with CKD G3a to G5D, we suggest that 25-(OH)D (calcidiol) levels might be measured, and repeated testing determined by baseline values and therapeutic interventions. (Grade 2C recommendation) We suggest that vitamin D deficiency and insufficiency be corrected using treatment strategies recommended for the general population. (Grade 2C recommendation)
3.1.4: In patients with CKD G3a to GSD, we recommend that therapeutic decisions be based on trends rather than on a single laboratory value, taking into account all available CKD-MBD assessments. (Grade 1C recommendation)
3.1.5: In patients with CKD G3a to G5D, we suggest that individual values of serum calcium and phosphate, evaluated together, be used to guide clinical practice rather than the mathematical construct of calcium-phosphate product (Ca × P). (Grade 2D recommendation)
3.1.6: In reports of laboratory tests for patients with CKD G3a to GSD, we recommend that clinical laboratories inform clinicians of the actual assay method in use and report any change in methods, sample source (plasma or serum), and handling specifications to facilitate the appropriate interpretation of biochemistry data. (Grade 1B recommendation)

Chapter 3.2: Diagnosis of CKD-MBD: Bone Abnormalities
3.2.1: In patients with CKD G3a to G5D with evidence of CKD-MBD and/or risk factors for osteoporosis, we suggest BMD testing to assess fracture risk if results will impact treatment decisions. (Grade 2B recommendation)
3.2.2: In patients with CKD G3a to G5D, it is reasonable to perform a bone biopsy if knowledge of the type of renal osteodystrophy will impact treatment decisions. (Not graded)
3.2.3: In patients with CKD G3a to G5D, we suggest that measurements of serum PTH or bone-specific alkaline phosphatase can be used to evaluate bone disease because markedly high or low values predict underlying bone turnover. (Grade 2B recommendation)
3.2.4: In patients with CKD G3a to G5D, we suggest not to routinely measure bone-derived turnover markers of collagen synthesis (such as procollagen type I-C-terminal propeptide) and breakdown (such as type I collagen cross-linked telopeptide, cross-laps, pyridinoline, or deoxypyridinoline). (Grade 2C recommendation)

Chapter 3.3: Diagnosis of CKD-MBD: Vascular Calcification
3.3.1: In patients with CKD G3a to G5D, we suggest that a lateral abdominal radiograph can be used to detect the presence or absence of vascular calcification, and an echocardiogram can be used to detect the presence or absence of valvular calcification, as reasonable alternatives to computed tomography-based imaging. (Grade 2C recommendation)

Table—Continued

Chapter 3.2.1: In patients with CKD G3a to G5D, we suggest that measurements of serum PTH or bone-specific alkaline phosphatase can be used to evaluate bone disease because markedly high or low values predict underlying bone turnover. (Grade 2B recommendation)

Chapter 4.1: Treatment of CKD-MBD Targeted at Lowering High Serum Phosphate and Maintaining Serum Calcium
4.1.1: In patients with CKD G3a to G5D, treatments of CKD-MBD should be based on serial assessments of phosphate, calcium, and PTH levels, considered together. (Not graded)
4.1.2: In patients with CKD G3a to G5D, we suggest lowering elevated phosphate levels toward the normal range. (Grade 2C recommendation)
4.1.3: In adult patients with CKD G3a to G5D, we suggest avoiding hypercalcemia. (Grade 2C recommendation)
4.1.4: In patients with CKD GSD, we suggest using a dialyzate calcium concentration between 1.25 and 1.50 mmol/L (2.5 and 3.0 mEq/L). (Grade 2C recommendation)

Chapter 4.2: Treatment of Abnormal PTH Levels in CKD-MBD
4.2.1: In patients with CKD G3a to G5D not on dialysis, the optimal PTH level is not known. However, we suggest that patients with levels of intact PTH progressively rising or persistently above the upper normal limit for the assay be evaluated for modifiable factors, including hyperparathyroidism, hypocalcemia, high phosphate intake, and vitamin D deficiency. (Grade 2C recommendation)
4.2.2: In adult patients with CKD G3a to G5D not on dialysis, we suggest that calcitriol and vitamin D analogues not be routinely used. (Grade 2C recommendation) It is reasonable to reserve the use of calcitriol and vitamin D analogues for patients with CKD G4 to G5 with severe and progressive hyperparathyroidism. (Not graded)
4.2.3: In patients with CKD GSD, we suggest maintaining iPTH levels in the range of approximately two to nine times the upper normal limit for the assay. (Grade 2C recommendation)
We suggest that marked changes in PTH levels in either direction within this range prompt an initiation or change in therapy to avoid progression to levels outside of this range. (Grade 2C recommendation)
4.2.4: In patients with CKD GSD requiring PTH-lowering therapy, we suggest calcimimetics, calcitriol, or vitamin D analogues, or a combination of calcimimetics with calcitriol or vitamin D analogues. (Grade 2B recommendation)
4.2.5: In patients with CKD G3a to G5D with severe hyperparathyroidism (HPT) who fail to respond to medical or pharmacological therapy, we suggest parathyroidectomy. (Grade 2B recommendation)

Chapter 4.3: Treatment of Bone With Bisphosphonates, Other Osteoporosis Medications, and Growth Hormone
4.3.1: In patients with CKD G3a to G5B with PTH in the normal range and osteoporosis and/or high risk of fracture, as identified by World Health Organization criteria, we suggest treatment as for the general population. (Grade 2B recommendation)
The evidence review also examined results from 3 new clinical trials that studied the effects of osteoporosis medications on BMD in CKD stage G3a to G5D (9–11). However, the studies did not show consistent beneficial effects of osteoporosis medications.

3.2.2: In patients with CKD G3a to G5D, it is reasonable to perform a bone biopsy if knowledge of the type of renal osteodystrophy will impact treatment decisions. (Not graded)

Bone biopsy is the gold standard for diagnosis and classification of renal osteodystrophy (12). The 2009 guideline noted that DXA BMD testing does not distinguish among types of renal osteodystrophy, and the diagnostic utility of biochemical markers was limited by their poor sensitivity and specificity (1). A study of bone biopsies from 492 patients receiving dialysis (13) found that no biomarker (alone or in combination with others) was sufficiently robust to diagnose low, normal, and high bone turnover in individual patients. Differences in PTH assays have also contributed to conflicting results across studies.

Due to these considerations, therapeutic decisions should be based on trends in serum PTH levels instead of 1-time values. When PTH trends are inconsistent, it is reasonable to perform bone biopsy if the results could lead to changes in therapy.

The 2009 guideline recommended bone biopsy before antiresorptive therapy in patients with CKD stage G4 to G5D and evidence of biochemical abnormalities of CKD-MBD, low BMD, and/or fragility fractures (1). However, due to limited clinical experience with performance of bone biopsy and evaluation of the results (14), as well as growing evidence that antiresorptive therapies are effective in patients with CKD stage G3a to G4, bone biopsy is no longer a prerequisite for initiation of these therapies.

**UPDATED RECOMMENDATIONS RELATING TO MANAGEMENT OF SERUM PHOSPHATE AND CALCIUM LEVELS**

4.1.1: In patients with CKD G3a to G5D, treatments of CKD-MBD should be based on serial assessments of phosphate, calcium, and PTH levels, considered together. (Not graded)

4.1.2: In patients with CKD G3a to G5D, we suggest lowering elevated phosphate levels toward the normal range. (Grade 2C recommendation)

In patients with CKD, clinical decisions are routinely based on serum phosphate, calcium, and PTH concentrations, and BMD testing may provide additional information to support these decisions.
CLINICAL GUIDELINE

Synopsis of the KDIGO 2017 Clinical Practice Guideline Update

trations. However, these are influenced by several factors, including diurnal changes (15, 16). A recent post hoc analysis of large dialysis cohorts suggested that the prognostic implications of individual biochemical components of CKD–MBD largely depend on their context within the full array of MBD biomarkers (17). This analysis identified a wide range of CKD–MBD phenotypes, based on phosphate, calcium, and PTH measurements segregated into mutually exclusive categories (low, medium, and high) using previous targets from the KDIGO guideline as well as earlier Kidney Disease Outcomes Quality Initiative guidelines. The analysis underscored the importance of potential interactions among components of CKD–MBD in terms of risk prediction for death or cardiovascular events. Treatments aimed at improving one variable often have unintended or intended effects on others (18). Thus, treatment decisions should be based not on a single laboratory value but on trends of serial measurements of phosphate, calcium, and PTH considered together.

High-quality evidence now links high phosphate concentrations with mortality among patients with CKD stage G3a to G5 and transplant recipients (19–28). However, there is still a lack of data from clinical trials showing that therapeutic approaches to decreasing serum phosphate levels improve patient-centered outcomes.

Methods for preventing hyperphosphatemia include diet modification, phosphate-lowering therapy, and intensified dialysis for patients with CKD stage G5D. The 2009 guideline suggested maintenance of normal serum phosphate levels for patients with CKD stages G3a to G4.

Most studies found phosphate to be consistently associated with excess mortality at levels above and below the limits of normal but not in the normal range. However, a recent trial comparing placebo with active phosphate binder therapy in patients with CKD who were not receiving dialysis (stage G3b or G4) and who had normal phosphate concentrations before initiation of binder treatment found a minimal decrease in serum phosphate levels, no effect on fibroblast growth factor 23 (FGF23) levels, and increases in coronary calcification scores in the active treatment group (29). This led to concerns about the efficacy and safety of phosphate binders in this population.

On the basis of the current evidence, the previous suggestion to maintain normal phosphate levels was abandoned; instead, treatment should be focused on patients with hyperphosphatemia. Prevention rather than treatment of hyperphosphatemia may be valuable in patients with CKD stage G3a to G5D, but future studies will need to address the potential value of hyperphosphatemia prevention in at-risk CKD populations (for example, patients with elevated FGF23 levels).

4.1.3: In adult patients with CKD G3a to G5D, we suggest avoiding hypercalcemia. (Grade 2C recommendation)

4.1.4: In patients with CKD G5D, we suggest using a dialysate calcium concentration between 1.25 and 1.50 mmol/L (2.5 and 3.0 mEq/L). (Grade 2C recommendation)

Similar to phosphate, new data support an association between higher calcium concentrations and increased mortality in adults with CKD (22–24, 27, 30–34). Higher serum calcium concentrations have also been linked to nonfatal cardiovascular events (35, 36).

Hypocalcemia contributes to the pathogenesis of secondary hyperparathyroidism (SHPT) and renal osteodystrophy, prompting the 2009 recommendation to suggest maintenance of normal serum calcium levels, including correction of hypocalcemia. However, whether the suggestion to correct hypocalcemia was generalizable to all CKD stages and all treatment conditions is unclear on the basis of recent studies. One consideration is the potential harm associated with a positive calcium balance in some cases (37, 38). The second consideration is that the prevalence of hypocalcemia may have increased after the introduction of calcimimetics (cinacalcet) in patients receiving dialysis (18, 39, 40). The clinical implications of this increased incidence are uncertain. On one hand, hypocalcemia represents the mode of action of calcimimetics and may positively contribute to bone mineralization. On the other hand, none of the pivotal trials or the phase 4 outcome trial EVOLVE (EValuation Of Cinacalcet Hydrochloride [HCl] Therapy to Lower CardioVascular Events) showed any adverse associations with mildly or moderately decreased calcium levels. The intention-to-treat analysis of the EVOLVE trial showed no association between negative signals and the persistently low serum calcium levels in the cinacalcet group (41).

The 2009 recommendation supported the concept that patients developing hypocalcemia during calcimimetic treatment require aggressive calcium treatment. Given the unproven benefits of calcimimetic treatment and the potential for harm, an individualized approach should be used to treat hypocalcemia rather than recommending correction of hypocalcemia in all patients. However, patients with significant or symptomatic hypocalcemia could still benefit from correction to prevent adverse consequences.

On the basis of new evidence (42, 43), the 2009 recommendation for dialysate calcium concentration was retained, but the evidence was upgraded from 2D to 2C.

4.1.5: In patients with CKD G3a to G5D, decisions about phosphate-lowering treatment should be based on progressively or persistently elevated serum phosphate. (Not graded)

4.1.6: In adult patients with CKD G3a to G5D receiving phosphate-lowering treatment, we suggest restricting the dose of calcium-based phosphate binders. (Grade 2B recommendation)

New pathophysiologic understanding of phosphate regulation and the roles of FGF23 and soluble Klotho in early CKD have prompted studies investigating phosphate-lowering therapies in patients with CKD who have not yet developed hyperphosphatemia. In a study of patients with CKD who were not receiving dialysis (stage G3b or G4), had a mean baseline serum
phosphate concentration of 1.36 mmol/L (4.2 mg/dL), and were treated with 3 phosphate binders (sevelamer, lanthanum, or calcium acetate) versus matching placebo (29), there was a small decrease in serum phosphate concentrations and a 22% decrease in urinary phosphate excretion (suggesting adherence to therapy) in the active treatment group; no differences in changes in FGF23 levels were observed versus placebo. Contrary to expectations, progression of coronary and aortic calcification was observed with active phosphate binder treatment (primarily due to calcium acetate) but not with placebo.

This study was supported by another metabolic study in a small group of patients with CKD stage G3b or G4, in whom the addition of calcium carbonate (equivalent to three 500-mg doses of elemental calcium) to 3 daily meals containing 1 g of calcium and 1.5 g of phosphorus did not affect baseline neutral phosphate balance but caused a positive short-term calcium balance (30). Although this study did not meet the criteria for full evidence review, it may present a plausible and relevant safety signal.

Both studies examined patients with essentially normal phosphate concentrations at baseline (29, 30). Two conclusions are apparent: Normophosphatemia may not be an indication to start phosphate-lowering treatments, and not all phosphate binders are interchangeable. The recommendation was updated to clarify that phosphate-lowering therapies may only be indicated in the event of progressive or persistent hyperphosphatemia and not for prevention.

The metabolic study (30) supported results of an earlier study suggesting the potential harm of liberal calcium exposure in normophosphatemic adults with CKD stage G3b or G4 (38). The earlier study also was not eligible for full evidence review.

These results, together with uncertainties about phosphate-lowering therapy in patients with CKD who are not receiving dialysis and results of additional randomized controlled trials (RCTs) with hard end points (29, 44, 45), prompted reevaluation of the 2009 recommendation with regard to calcium-based phosphate binders. The studies seemed to show either a potential for benefit or an absence of harm associated with calcium-free phosphate-binding agents compared with calcium-based agents for treatment of hyperphosphatemia.

The current evidence suggests that excess exposure to calcium may be harmful across all GFR categories of CKD. Despite the understandable desire to have numerical targets and limits, no explicit recommendation about a maximum dose of calcium-based binders was possible. Instead, phosphate-lowering treatment decisions should be individualized.

4.1.8: In patients with CKD G3a to G5D, we suggest limiting dietary phosphate intake in the treatment of hyperphosphatemia alone or in combination with other treatments. (Grade 2D recommendation) It is reasonable to consider phosphate source (e.g., animal, vegetable, additives) in making dietary recommendations. (Not graded)

There was no controversy about restricting dietary phosphate to decrease elevated phosphate levels, but the wording of the original statement was vague, especially in light of new evidence on different phosphate and phosphoprotein sources (processed vs. fresh food [46–49], vegetables vs. meat [15], and “hidden” sources [49, 50]). Given that studies on various types of nutrition education have had mixed results for control of serum phosphate levels, the original recommendation on dietary phosphate restriction was amended to acknowledge that phosphate sources should be better substantiated and patient education should focus on best choices.

Updated Recommendations Relating to Management of Serum PTH Levels

4.2.1: In patients with CKD G3a to G5 not on dialysis, the optimal PTH level is not known. However, we suggest that patients with levels of intact PTH progressively rising or persistently above the upper normal limit for the assay be evaluated for modifiable factors, including hyperphosphatemia, hypocalcemia, high phosphate intake, and vitamin D deficiency. (Grade 2C recommendation)

The pathogenesis of SHPT is complex and is driven by several factors, including vitamin D deficiency, hypocalcemia, and hyperphosphatemia. As kidney function decreases, the incidence and severity of SHPT increase, leading to abnormalities in bone mineralization and turnover.

Data from RCTs are insufficient to define an optimal PTH level for patients with CKD stage G3a to G5 or clinical end points of hospitalization, fracture, or death. Modest increases in PTH levels may represent an appropriate adaptive response to decreasing kidney function due to phosphaturic effects and increasing bone resistance to PTH (51). Therefore, the original recommendation was revised to reflect treatment based on trends in PTH level (highlighting levels “progressively rising or persistently above the upper normal limit”) rather than a single elevated value.

The data highlighted an additional modifiable risk factor for SHPT: high phosphate intake. This revision acknowledges that excess phosphate intake does not always result in hyperphosphatemia, especially in early CKD, but high intake may promote SHPT.

4.2.2: In adult patients with CKD G3a to G5 not on dialysis, we suggest that calcitriol and vitamin D analogues not be routinely used. (Grade 2C recommendation) It is reasonable to reserve the use of calcitriol and vitamin D analogues for patients with CKD G4 to G5 with severe and progressive hyperparathyroidism. (Not graded)

Prevention and treatment of SHPT are important because imbalances in mineral metabolism are associated with CKD-MBD, and higher PTH levels are associated with increased morbidity and mortality in patients with CKD. Although the 2009 guideline summarized multiple studies showing the ability of calcitriol or vitamin D analogues to decrease PTH levels, there was a
CLINICAL GUIDELINE

notable lack of trials demonstrating improvements in patient-centered outcomes. Recent RCTs of calcitriol or vitamin D analogues have supplemented the evidence base.

A double-blind RCT (PRIMO [Paricalcitol Capsule Benefits in Renal Failure-Induced Cardiac Morbidity]) in patients with CKD stage G3a to G5, mild to moderate left ventricular hypertrophy (LVH), and PTH levels of 50 to 300 pg/mL compared paricalcitol with placebo to test the primary hypothesis that paricalcitol reduces left ventricular mass index (LVMI) over 48 weeks (52). The intention-to-treat analysis revealed that paricalcitol did not reduce LVMI and did not modify diastolic function. The mean serum calcium level increased by 0.08 mmol/L (0.32 mg/dL) in the paricalcitol group versus a decrease of 0.06 mmol/L (0.25 mg/dL) in the placebo group. Episodes of hypercalcemia were more common in the paricalcitol group (22.6%) than the placebo group (9%).

In another double-blind RCT (OPERA [Oral Paricalcitol in Stage 3-5 Chronic Kidney Disease]), patients with CKD stage G3a to G5, LVH, and PTH levels of 55 pg/mL or greater were randomly assigned to receive paricalcitol or placebo (53). The primary end point (change in LVMI over 52 weeks) and secondary outcomes (such as measures of systolic and diastolic function) did not differ between groups. The median changes in serum calcium level were 0.08 mmol/L (0.32 mg/dL) and 0.01 mmol/L (0.04 mg/dL) in the paricalcitol and placebo groups, respectively. Hypercalcemia (serum calcium level >2.55 mmol/L [>10.2 mg/dL]) was observed in 43.3% and 3.3% of participants in the paricalcitol and placebo groups, respectively; 70% of hypercalcemic patients received concomitant calcium-based phosphate binders. Hypercalcemia could be corrected by stopping use of the binder without changing the paricalcitol dose.

The results from the PRIMO and OPERA studies were supported by recent meta-analyses (54, 55). The Work Group agreed that the risk–benefit ratio for treating moderate PTH elevations was no longer favorable. Therefore, use of calcitriol or vitamin D analogues should be reserved for severe and progressive SHPT.

4.2.4: In patients with CKD G5D requiring PTH-lowering therapy, we suggest calcimimetics, calcitriol, or vitamin D analogues, or a combination of calcimetics with calcitriol or vitamin D analogues. (Grade 2B recommendation)

Use of PTH-lowering therapies in patients with CKD stage G5D was reappraised on the basis of new studies of cinacalcet and vitamin D analogues, with a focus on the EVOLVE trial (41). No new trials of calcitriol or vitamin D analogues with patient-level end points were identified.

The EVOLVE trial evaluated the effect of cinacalcet versus placebo on patient-level outcomes in 3883 patients receiving hemodialysis, using a composite end point of all-cause mortality, nonfatal myocardial infarction, hospitalization for unstable angina, congestive heart failure, and peripheral vascular events (41). The unadjusted primary composite end point showed a statistically nonsignificant reduction (hazard ratio, 0.93; P = 0.112) with cinacalcet, but analyses adjusted for imbalances in baseline characteristics showed that this reduction was nominal (hazard ratio, 0.88; P = 0.008). Further, an interaction between treatment and age (P = 0.04) led to speculation that cinacalcet may be effective predominantly in older patients receiving dialysis.

No consensus was reached about whether the EVOLVE data were sufficient to recommend cinacalcet as a first-line option for all patients with SHPT and CKD stage G5D who require PTH-lowering therapy. One opinion is that the primary end point of the EVOLVE trial was negative. The alternative opinion is that secondary analyses found effects on patient-level end points, whereas there are no positive data on mortality or patient-centered end points from trials of calcitriol or other vitamin D analogues.

Given the lack of consensus and the higher acquisition cost of cinacalcet, the revised recommendation for PTH-lowering therapy in patients with CKD stage G5D now lists all acceptable treatment options in alphabetical order. Treatment choice should be guided by individual considerations about concomitant therapies and the patient’s current calcium and phosphate levels.

UPDATED RECOMMENDATION RELATING TO TREATMENT OF BONE ABNORMALITIES WITH BISPHOSPHONATES AND OTHER OSTEOPOROSIS MEDICATIONS

4.3.3: In patients with CKD G3a to G5D with biochemical abnormalities of CKD-MBD and low BMD and/or fragility fractures, we suggest that treatment choices take into account the magnitude and reversibility of the biochemical abnormalities and the progression of CKD, with consideration of a bone biopsy. (Grade 2D recommendation)

This recommendation serves as a reminder that when treatment choices are considered, their adverse effects must also be taken into account (for example, antiresorptives exacerbate low bone turnover, and denosumab may induce significant hypocalcemia) and the risks of administering antiresorptives must be weighed against the accuracy of the diagnosis of the underlying bone phenotype.

DISCUSSION

The process of updating the 2009 CKD-MBD guideline to accommodate data from new studies found that many of the original recommendations remain current. Overall, 15 recommendations were revised.

Prospective studies evaluating BMD testing in adults with CKD represent a substantial advance since the original CKD-MBD guideline was published. The data support use of DXA BMD testing if the results will
Synopsis of the KDIGO 2017 Clinical Practice Guideline Update

CLINICAL GUIDELINE

Affect future treatment. Because such testing does not distinguish among types of renal osteodystrophy, bone biopsy remains the diagnostic gold standard. For patients at high risk for fracture, facilities that lack the ability to perform bone biopsy or evaluate the results should not withhold antiresorptive therapy.

The interplay among biochemical variables (serum phosphate, calcium, and PTH) in patients with CKD-MBD received considerable attention during the review of the current evidence. It is apparent that therapeutic maneuvers aimed at improving one variable often have unintended effects on others. Thus, treatment approaches for CKD-MBD should be based on serial assessments of these variables taken together.

Current evidence does not show benefit to maintaining normal serum phosphate levels in patients not receiving dialysis, and there are safety concerns associated with aggressive phosphate-lowering therapy. Thus, treatment should focus on patients with overt hyperphosphatemia. In the case of calcium, new evidence suggests that hypercalcemia may be harmful in all GFR categories of CKD, prompting the recommendation to avoid inappropriate calcium loading in adults whenever possible. Use of calcium-based phosphate binders should also be restricted in patients with hyperphosphatemia across the CKD spectrum.

The 2009 recommendations for treatment of SHPT were expanded to reflect that modest increases in PTH may represent an appropriate adaptive response to decreasing kidney function. The current recommendation is to treat patients with PTH values that are progressively increasing or persistently above the upper limit of normal and not to base treatment on a single elevated value. Treatment approaches for SHPT in patients not receiving dialysis should not include routine use of calcitriol or vitamin D analogues due to the increased risk for hypercalcemia. Calcimimetics, calcitriol, and vitamin D analogues are acceptable first-line options in patients receiving dialysis.

Despite the recent clinical trials discussed in the updated guideline, significant gaps remain in the knowledge base for treatment of CKD-MBD, as demonstrated by the relatively small number of recommendations updated in the 2017 guideline. Future research should address many of these gaps. For example, RCTs should be conducted to compare the ability of calcium-containing and calcium-free phosphate binders to promote bone accrual, as well as their effect on arterial calcification. Studies on dietary phosphate intake should compare phosphate sources (vegetable, meat, or “hidden” sources [such as food additives]). Prospective trials should use a benefit-risk-cost ratio to identify the most effective phosphate-lowering approach across all CKD GFR categories; such studies should include patient-centered and surrogate end points, including vascular calcification, FGF23 levels, and LVH. Multicenter studies examining patient-level outcomes are needed to determine the benefits and risks of treatment with calcitriol or vitamin D analogues in patients with CKD stage G3a to G5 and mild or severe SHPT. Placebo-controlled trials are also needed to compare calcimimetics with standard therapy in patients with CKD stage G5D and SHPT, with an emphasis on FGF23 reduction as a therapeutic end point.

From Klinikum Coburg, Coburg, Germany, and University of Split School of Medicine, Split, Croatia; Denver Nephrology, Denver, Colorado; University Hospitals Leuven, Leuven, Belgium; Tokai University School of Medicine, Isehara, Japan; Hennepin County Medical Center and University of Minnesota, Minneapolis, Minnesota; Eagle, Idaho; Indiana University School of Medicine and Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana; Great Ormond Street Hospital for Children, NHS Foundation Trust, London, United Kingdom; University of Calgary, Calgary, Alberta, Canada; The Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia; VU University Medical Center Amsterdam, Amsterdam, the Netherlands; and Stanford University School of Medicine, Stanford, California.

Acknowledgment: The Work Group thanks Bertram L. Kasiske and the KDIGO Co-Chairs, David C. Wheeler and Wolfgang C. Winkelmaier, for their invaluable guidance. The Work Group is also grateful for the rigorous evidence review performed by Dr. Karen A. Robinson and her evidence review team members. Finally, the Work Group acknowledges all who provided feedback during the public review of the draft guideline.

Financial Support: This guideline is supported by KDIGO, and no funding is accepted for the development of specific guidelines.

Disclosures: Dr. Ketteler reports grants from Amgen and personal fees from Amgen, Fresenius Medical Care, Medice, Sanofi, and Vifor Fresenius Medical Care Renal Pharma outside the submitted work. Dr. Block reports personal fees from Amgen, Kirin Corporation, OPKO, Daiichi Sankyo, ONO Pharmaceutical, Keryx, and Ardelyx; nonfinancial support from Amgen, OPKO, ONO Pharmaceutical, and Keryx; grants from Keryx; and other support from Ardelyx outside the submitted work. Dr. Evenepoel reports grants from Amgen and personal fees from Amgen, Sanofi, and Vifor Fresenius Medical Care during the conduct of the study. Dr. Fukagawa reports grants from Kyowa Hakko Kirin and Bayer Japan and personal fees from Kyowa Hakko Kirin, Bayer Japan, ONO Pharmaceutical, and Torii Pharmaceutical outside the submitted work. Dr. Herzog reports grants from Amgen and Zoll and personal fees from AbbVie, FibroGen, Relypsa, Sanifit, and ZS Pharma outside the submitted work. Ms. McCann reports other support from Amgen, Sanofi, and Relypsa outside the submitted work. Dr. Moe reports grants from Chugai, the National Institutes of Health, and the U.S. Department of Veterans Affairs and personal fees from Sanofi Genzyme and Amgen outside the submitted work. Dr. Toussaint reports grants and nonfinancial support from Amgen, Shire, and Sanofi during the conduct of the study. Dr. Vervloet reports grants from Fresenius Medical Care, Vifor Pharma, and Amgen and personal fees from Fresenius Medical Care, Vifor Pharma, Otsuka, Baxter, and Amgen outside the submitted work. Authors not named here have disclosed no conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2640. All Work Group members are required to complete, sign, and submit a financial disclosure and attestation form showing all such relationships.

Annals.org

Annals of Internal Medicine

7

Downloaded From: http://annals.org/ by a NYU Medical Center Library User on 02/20/2018
that might be perceived as or are actual conflicts of interest. All reported information is published in the Work Group members’ Biographic and Disclosure section, which can be found in the full-text guideline update (http://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf).

References


Synopsis of the KDIGO 2017 Clinical Practice Guideline Update


Current Author Addresses: Dr. Ketteler: Division of Nephrology, Klinikum Coburg GmbH, Ketschendorfer Street 33, 96450 Coburg, Germany.
Dr. Block: Denver Nephrology, 130 Rampart Way, Suite 175, Denver, CO 80230.
Dr. Evenepoel: University Hospitals Leuven, Herestraat 49, Leuven 3000, Belgium.
Dr. Fukagawa: Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, 143 Shimo-kasuya, Isehara 2591193, Japan.
Dr. Herzog: Hennepin County Medical Center/University of Minnesota, 914 South 8th Street, Suite S-4.100, Minneapolis, MN 55404.
Dr. Moe: Indiana University, 950 West Walnut Street, R2-202, Indianapolis, IN 46202.
Dr. Shroff: Great Ormond Street Hospital for Children, NHS Foundation Trust, Great Ormond Street, London WC1N 3JH, United Kingdom.
Dr. Tonelli: University of Calgary, TRW 7th Floor, 3280 Hospital Drive Northwest, Calgary, Alberta T6G 2G3, Canada.
Dr. Toussaint: The Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria 3050, Australia.
Dr. Vervloet: VU University Medical Center, De Boelelaan 1117, 1081 HV Amsterdam, the Netherlands.
Dr. Leonard: Stanford University School of Medicine, 300 Pasteur Drive, Room G-306, Stanford, CA 94305.

Author Contributions: Conception and design: M. Ketteler, G.A. Block, M. Fukagawa, S.M. Moe, R. Shroff, N.D. Toussaint, M.G. Vervloet.
Analysis and interpretation of the data: M. Ketteler, G.A. Block, P. Evenepoel, L. McCann, S.M. Moe, R. Shroff, M.A. Tonelli, N.D. Toussaint, M.G. Vervloet.
Drafting of the article: M. Ketteler, G.A. Block, L. McCann, R. Shroff, N.D. Toussaint, M.G. Vervloet.
Critical revision of the article for important intellectual content: M. Ketteler, G.A. Block, P. Evenepoel, C.A. Herzog, L. McCann, S.M. Moe, R. Shroff, M.A. Tonelli, N.D. Toussaint, M.G. Vervloet.
Administrative, technical, or logistic support: M.B. Leonard.
Collection and assembly of data: M. Ketteler, G.A. Block, P. Evenepoel, M. Fukagawa, L. McCann, N.D. Toussaint, M.G. Vervloet.

Appendix Figure. Prognosis of CKD, by categories of GFR and albuminuria.

<table>
<thead>
<tr>
<th>Persistent Albuminuria Categories</th>
<th>Description and Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>Normal to mildly increased</td>
</tr>
<tr>
<td>A2</td>
<td>Moderately increased</td>
</tr>
<tr>
<td>A3</td>
<td>Severely increased</td>
</tr>
<tr>
<td>&lt;30 mg/g</td>
<td>30–300 mg/g</td>
</tr>
<tr>
<td>&lt;3 mg/mmol</td>
<td>&gt;300 mg/g</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GFR Categories (mL/min/1.73 m²)</th>
<th>Description and Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1</td>
<td>Normal or high ≥90</td>
</tr>
<tr>
<td>G2</td>
<td>Mildly decreased 60–89</td>
</tr>
<tr>
<td>G3a</td>
<td>Mildly to moderately decreased 45–59</td>
</tr>
<tr>
<td>G3b</td>
<td>Moderately to severely decreased 30–44</td>
</tr>
<tr>
<td>G4</td>
<td>Severely decreased 15–29</td>
</tr>
<tr>
<td>G5</td>
<td>Kidney failure &lt;15</td>
</tr>
</tbody>
</table>

CKD is defined as abnormalities of kidney structure or function that are present for >3 mo and have health implications. CKD is classified on the basis of cause, GFR category (G1 to G5), and albuminuria category (A1 to A3). Green means low risk (no CKD if no other markers of kidney disease), yellow means moderately increased risk, orange means high risk, and red means very high risk. The suffix “D” denotes dialysis (e.g., CKD G5D refers to a patient with CKD stage G5 who is receiving dialysis). (Reproduced with permission of Kidney Disease: Improving Global Outcomes.) CKD = chronic kidney disease; GFR = glomerular filtration rate.
### Appendix Table 1. GRADE Criteria Used for Grading the Strength of a Recommendation*

<table>
<thead>
<tr>
<th>Grade</th>
<th>Patients</th>
<th>Implications</th>
<th>Policy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Level 1: “We recommend”</td>
<td>Most people in your situation would want the recommended course of action, and only a small proportion would not.</td>
<td>Most patients should receive the recommended course of action.</td>
<td>The recommendation can be evaluated as a candidate for developing a policy or a performance measure.</td>
</tr>
<tr>
<td>Level 2: “We suggest”</td>
<td>The majority of people in your situation would want the recommended course of action, but many would not.</td>
<td>Different choices will be appropriate for different patients. Each patient needs help to arrive at a management decision consistent with her or his values and preferences.</td>
<td>The recommendation is likely to require debate and involvement of stakeholders before policy can be determined.</td>
</tr>
</tbody>
</table>

GRADE = Grading of Recommendations Assessment, Development and Evaluation.

* The additional category “not graded” is typically used to provide guidance based on common sense or when the topic does not allow adequate application of evidence. The most common examples include recommendations regarding monitoring intervals, counseling, and referral to other clinical specialists. The ungraded recommendations are generally written as simple declarative statements but are not meant to be interpreted as being stronger recommendations than level 1 or 2 recommendations.

### Appendix Table 2. GRADE Criteria Used for Grading the Overall Quality of Evidence

<table>
<thead>
<tr>
<th>Grade</th>
<th>Quality of Evidence</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>High</td>
<td>We are confident that the true effect lies close to that of the estimate of the effect.</td>
</tr>
<tr>
<td>B</td>
<td>Moderate</td>
<td>The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.</td>
</tr>
<tr>
<td>C</td>
<td>Low</td>
<td>The true effect may be substantially different from the estimate of the effect.</td>
</tr>
<tr>
<td>D</td>
<td>Very low</td>
<td>The estimate of the effect is very uncertain and often will be far from the truth.</td>
</tr>
</tbody>
</table>

GRADE = Grading of Recommendations Assessment, Development and Evaluation.
### Appendix Table 3. Research Questions Addressing the Systematic Update of Selected Recommendations

<table>
<thead>
<tr>
<th>2009 Recommendation Number</th>
<th>Research Question</th>
<th>Key Outcomes</th>
<th>Additional Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bone quality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.2.1</td>
<td>In patients with CKD G3a to G5D, what is the effect on bone quality of bisphosphonates, teriparatide, denosumab, and raloxifene?</td>
<td>TMV (as measured by bone biopsy) BMD/bone mineral content Fracture</td>
<td>-</td>
</tr>
<tr>
<td>4.3.4</td>
<td>In patients with CKD G4 to G5D, what is the effect on bone quality of bisphosphonates, teriparatide, denosumab, and raloxifene?</td>
<td>TMV (as measured by bone biopsy) BMD/bone mineral content Fracture</td>
<td>-</td>
</tr>
<tr>
<td>3.2.2</td>
<td>In patients with CKD G3a to G5D, how well do BMD results predict fractures?</td>
<td>Fracture</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>In patients with CKD G3a to G5D, how well do BMD results predict renal osteodystrophy?</td>
<td>TMV</td>
<td></td>
</tr>
<tr>
<td>Calcium and phosphate</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.1.1</td>
<td>In patients with CKD G3a to G5 or G5D, what is the evidence for benefit or harm in maintaining serum phosphate in the normal range compared with other targets of serum phosphate in terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?</td>
<td>Mortality GFR decline Cardiovascular and cerebrovascular events</td>
<td>Phosphate Bone histology, BMD Vascular and valvular calcification imaging Hospitalizations Quality of life Kidney or kidney graft failure Fracture Parathyroidectomy Clinical adverse events Growth, skeletal deformities, bone accrual Calciphylaxis/CUA</td>
</tr>
<tr>
<td>4.1.3</td>
<td>In patients with CKD G5D, what is the evidence for benefit or harm in using a dialysate calcium concentration between 1.25 and 1.50 mmol/L (2.5 and 3.0 mEq/L) compared with other concentrations of dialysate calcium in terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?</td>
<td>Mortality Cardiovascular and cerebrovascular events</td>
<td>Calcium Bone histology, BMD Vascular and valvular calcification imaging Measures of GFR Hospitalizations Quality of life Kidney or kidney graft failure Fracture Parathyroidectomy Clinical adverse events Growth, skeletal deformities, bone accrual Calciphylaxis/CUA</td>
</tr>
<tr>
<td>4.1.2</td>
<td>In patients with CKD G3a to G5D, what is the evidence for benefit or harm in maintaining serum calcium in the normal range compared with other targets of serum calcium in terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?</td>
<td>Mortality Cardiovascular and cerebrovascular events</td>
<td>Calcium Bone histology, BMD Vascular and valvular calcification imaging Measures of GFR Hospitalizations Quality of life Kidney or kidney graft failure Fracture Parathyroidectomy Clinical adverse events Growth, skeletal deformities, bone accrual Calciphylaxis/CUA</td>
</tr>
<tr>
<td>4.1.4</td>
<td>In patients with CKD G3a to G5 or G5D with hyperphosphatemia, what is the evidence for benefit or harm in using calcium-containing phosphate-binding agents to treat hyperphosphatemia compared with calcium-free phosphate-binding agents in terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?</td>
<td>Mortality Cardiovascular and cerebrovascular events</td>
<td>Phosphate Bone histology, BMD Vascular and valvular calcification imaging Measures of GFR Hospitalizations Quality of life Kidney or kidney graft failure Fracture Parathyroidectomy Clinical adverse events Growth, skeletal deformities, bone accrual Calciphylaxis/CUA</td>
</tr>
</tbody>
</table>

Continued on following page
### Appendix Table 3—Continued

<table>
<thead>
<tr>
<th>2009 Recommendation Number</th>
<th>Research Question</th>
<th>Key Outcomes</th>
<th>Additional Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1.7</td>
<td>In patients with CKD G3a to G5D with hyperphosphatemia, what is the evidence for benefit or harm in limiting dietary phosphate intake compared with a standard diet in terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?</td>
<td>Mortality Cardiovascular and cerebrovascular events Vascular and valvular calcification</td>
<td>Phosphate Bone histology, BMD Measures of GFR Hospitalizations Quality of life Kidney or kidney graft failure Fracture Parathyroidectomy Clinical adverse events Growth, skeletal deformities, bone accrual Calciphylaxis/CUA</td>
</tr>
<tr>
<td><strong>Vitamin D and PTH</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.2.1</td>
<td>In patients with CKD G3a to G5 not receiving dialysis with levels of intact PTH above the upper normal limit, what is the evidence for benefit or harm in reducing dietary phosphate intake or treating with phosphate-binding agents, calcium supplements, or native vitamin D in terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?</td>
<td>Mortality Cardiovascular and cerebrovascular events GFR decrease</td>
<td>Calcium Phosphate PTH 25-(OH)D 1,25-(OH)₂D Alkaline phosphatases Bone-specific alkaline phosphatase Bicarbonate FGF23 Bone histology, BMD Vascular and valvular calcification imaging Measures of GFR Hospitalizations Quality of life Kidney or kidney graft failure Fracture Parathyroidectomy Clinical adverse events Growth, skeletal deformities, bone accrual Calciphylaxis/CUA</td>
</tr>
<tr>
<td>4.2.2</td>
<td>In patients with CKD G3a to G5 not receiving dialysis in whom serum PTH is progressively increasing and remains persistently above the upper normal limit despite correction of modifiable factors, what is the evidence for benefit or harm in treating with calcitriol or vitamin D analogues compared with placebo or active control in terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?</td>
<td>LVH Hypercalcemia Mortality Cardiovascular and cerebrovascular events</td>
<td>Calcium Phosphate PTH 25-(OH)D 1,25-(OH)₂D Alkaline phosphatases Bone-specific alkaline phosphatase Bicarbonate FGF23 Bone histology, BMD Vascular and valvular calcification imaging Measures of GFR Hospitalizations Quality of life Kidney or kidney graft failure Fracture Parathyroidectomy Clinical adverse events Growth, skeletal deformities, bone accrual Calciphylaxis/CUA</td>
</tr>
</tbody>
</table>

*Continued on following page*
### Appendix Table 3—Continued

<table>
<thead>
<tr>
<th>2009 Recommendation Number</th>
<th>Research Question</th>
<th>Key Outcomes</th>
<th>Additional Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.2.4</td>
<td>In patients with CKD G5D, what is the evidence for benefit or harm in treating with calcitriol, vitamin D analogues, calcimimetics, or a combination thereof compared with placebo or active control in terms of biochemical outcomes, other surrogate outcomes, and patient-centered outcomes?</td>
<td>Mortality Cardiovascular and cerebrovascular events Fracture Vascular and valvar calcification imaging</td>
<td>Calcium Phosphate PTH 25-(OH)D 1,25-(OH)₂D Alkaline phosphatases Bone-specific alkaline phosphatase Bicarbonate FGF23 Bone histology, BMD Vascular and valvar calcification imaging Measures of GFR Hospitalizations Quality of life Kidney or kidney graft failure Fracture Parathyroidectomy Clinical adverse events Growth, skeletal deformities, bone accrual Calciphylaxis/CUA</td>
</tr>
</tbody>
</table>

1,25-(OH)₂D = 1,25-dihydroxyvitamin D; 25-(OH)D = 25-hydroxyvitamin D; BMD = bone mineral density; CKD = chronic kidney disease; CUA = calcific uremic arteriolopathy; FGF23 = fibroblast growth factor 23; GFR = glomerular filtration rate; LVH = left ventricular hypertrophy; PTH = parathyroid hormone; TMV = bone turnover mineralization volume.